Blood filter shows promise for liver failure patients

NCT ID NCT05030571

Recruiting now Disease control Sponsor: Chulalongkorn University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a blood-filtering device called DPMAS can help people with acute-on-chronic liver failure, a life-threatening condition. The device removes toxins and inflammatory substances from the blood, which may improve immune function and survival. Forty intensive care patients will be randomly assigned to receive either standard care alone or standard care plus DPMAS.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Double plasma molecular adsorption system (DPMAS) – a blood-filtering device that removes toxins and inflammatory substances from the blood
What this could lead to: If it works, DPMAS could become a standard add-on treatment to improve immune function and survival in acute-on-chronic liver failure.
What could go wrong: This is a small early-stage trial with only 40 participants, so results may not apply broadly. The device is not a cure and is used alongside standard care; benefits are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE ON CHRONIC HEPATIC FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Acute-On-Chronic Liver Failure liver failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE ON CHRONIC HEPATIC FAILURE ACUTE-ON-CHRONIC LIVER FAILURE

Contacts and locations

Locations

King Chulalongkorn Memorial Hospital
RECRUITING

Bangkok, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.